Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2
July 01, 2020 12:06 ET | Source: Sorrento Therapeutics, Inc. T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc. Novel protein to progress as priority vaccine candidate development program.Sorrento’s existing cGMP manufacturing facility bulk drug substance production capacity estimated able to satisfy up to 100 million doses a month, with on-site scale-up potential to meet additional demand as needed. SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. ( Nasdaq: SRNE, “Sorrento”) announced today that it has published a pre- print publication (https://www.biorxiv.org/content/10.1101/2020.06.29. 178616v1.full.pdf) describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine against COVID-19, referred to as T-VIVA-19.
T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc). The rS1-Fc was injected into either the vein or the thigh muscle of a mouse. The mice were given a booster shot three weeks later (by the same route as the initial injection) and immune responses to SARS-CoV-2 were examined.
Immunization with the rS1-Fc protein via intramuscular and intravenous injections induced antibodies against the SARS-CoV-2 protein in all mice within the first week of administration. Antibodies were observed to be enhanced upon the administration of a booster. Approximately 80% of the mice’s sera possessed neutralizing antibodies and completely prevented virus infection in in vitro cell cultures using 100 TCID50 viruses and VERO cells.
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said, “If successful and approved, we plan to produce the T-VIVA-19 vaccine in our therapeutic antibody cGMP production facility in San Diego. Due to the potentially low dose administration of T-VIVA-19, which may be one milligram per person or less, we believe our existing cGMP manufacturing facility is capable of producing bulk drug substance rS1-Fc for up to 100 million doses a month. Unlike other vaccine candidates, our rS1-Fc protein production could utilize our existing therapeutic antibody manufacturing processes, and we therefore believe it would be simple and easy to scale up.”
Sorrento plans to take the T-VIVA-19 vaccine candidate through the regulatory steps for clinical trial clearance, while preparing for large scale manufacturing and commercial distribution in parallel.
【 以下文字转载自 Military 讨论区 】
发信人: lubbock12 (非老非小将), 信区: Military
标 题: 日啊，季博士公司又弄出个特别变态的新产品
发信站: BBS 未名空间站 (Wed Jul 1 17:05:56 2020, 美东)
把新冠的spike蛋白直接嫁接到人抗体重链区Fc上，然后当疫苗使用，给老鼠注射后，
产生了中和抗体，季博士说由于需要引发免疫反应的量特别少，他可以一个月生产一亿剂。
Sorrento Announces Selection of T-VIVA-19™ as Targeted Protein Vaccine Candidate for SARS-CoV-2
July 01, 2020 12:06 ET | Source: Sorrento Therapeutics, Inc.
T-VIVA-19 (targeted virus vaccine against COVID-19) is a recombinant fusion protein of the SARS-CoV-2 spike protein S1 domain and human IgG Fc.
Novel protein to progress as priority vaccine candidate development program.Sorrento’s existing cGMP manufacturing facility bulk drug substance
production capacity estimated able to satisfy up to 100 million doses a
month, with on-site scale-up potential to meet additional demand as needed.
SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (
Nasdaq: SRNE, “Sorrento”) announced today that it has published a pre-
print publication (https://www.biorxiv.org/content/10.1101/2020.06.29.
178616v1.full.pdf) describing initial pre-clinical results from its COVID-19 vaccination program, which introduced a novel targeted protein vaccine
against COVID-19, referred to as T-VIVA-19.
T-VIVA-19 is a recombinant fusion protein of the spike protein S1-domain and the Fc portion of the human IgG1 antibody (rS1-Fc). The rS1-Fc was injected into either the vein or the thigh muscle of a mouse. The mice were given a booster shot three weeks later (by the same route as the initial injection) and immune responses to SARS-CoV-2 were examined.
Immunization with the rS1-Fc protein via intramuscular and intravenous
injections induced antibodies against the SARS-CoV-2 protein in all mice
within the first week of administration. Antibodies were observed to be
enhanced upon the administration of a booster. Approximately 80% of the mice’s sera possessed neutralizing antibodies and completely prevented virus
infection in in vitro cell cultures using 100 TCID50 viruses and VERO cells.
Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said, “If
successful and approved, we plan to produce the T-VIVA-19 vaccine in our
therapeutic antibody cGMP production facility in San Diego. Due to the
potentially low dose administration of T-VIVA-19, which may be one milligram per person or less, we believe our existing cGMP manufacturing facility is capable of producing bulk drug substance rS1-Fc for up to 100 million doses a month. Unlike other vaccine candidates, our rS1-Fc protein production
could utilize our existing therapeutic antibody manufacturing processes, and we therefore believe it would be simple and easy to scale up.”
Sorrento plans to take the T-VIVA-19 vaccine candidate through the
regulatory steps for clinical trial clearance, while preparing for large
scale manufacturing and commercial distribution in parallel.
5月份炒作，FDA开始调查，股民起诉！季慱士又吹牛了
他的文章我都看完了，你看完了没有？
【 在 oaks18 (Oaks) 的大作中提到: 】
: 5月份炒作，FDA开始调查，股民起诉！季慱士又吹牛了
AZ和辉瑞的疫苗都失败了，该让季博士的疫苗试试了吧。